{"id":3924,"date":"2019-04-18T07:07:00","date_gmt":"2019-04-18T07:07:00","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&p=3924"},"modified":"2024-05-02T11:11:51","modified_gmt":"2024-05-02T09:11:51","slug":"granulocyte-monocyte-apheresis-an-alternative-combination-therapy-after-loss-of-response-to-anti-tnf-agents-in-ulcerative-colitis","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/es\/professional\/scientific-corner\/granulocyte-monocyte-apheresis-an-alternative-combination-therapy-after-loss-of-response-to-anti-tnf-agents-in-ulcerative-colitis\/","title":{"rendered":"Granulocyte-monocyte apheresis: an alternative combination therapy after loss of response to anti-TNF agents in ulcerative colitis."},"content":{"rendered":"
\n

Iago Rodr\u00edguez-Lago<\/a> 1<\/a><\/sup>, Laura Sempere<\/a> 2<\/a><\/sup>, Ana Guti\u00e9rrez<\/a> 2<\/a> 3<\/a><\/sup>, Andrea N\u00fa\u00f1ez<\/a> 4<\/a><\/sup>, Eduardo Leo Carnerero<\/a> 4<\/a><\/sup>, Esther Hinojosa<\/a> 5<\/a><\/sup>, Mar\u00eda Mora<\/a> 5<\/a><\/sup>, Fiorella Ca\u00f1ete<\/a> 6<\/a><\/sup>, Miriam Ma\u00f1osa<\/a> 6<\/a><\/sup>, Claudia Herrera<\/a> 7<\/a><\/sup>, Bel\u00e9n Beltr\u00e1n<\/a> 8<\/a><\/sup>, Ana For\u00e9s<\/a> 9<\/a><\/sup>, Dolores Arjona<\/a> 10<\/a><\/sup>, Manuel Barreiro-de Acosta<\/a> 11<\/a><\/sup>, Sam Khorrami<\/a> 12<\/a><\/sup>, Urko Aguirre<\/a> 13<\/a><\/sup>, Daniel Ginard<\/a> 12<\/a><\/sup>, Jos\u00e9 Luis Cabriada<\/a> 1<\/a><\/sup> , Scand J Gastroenterol 2019 Apr;54(4):459-464.<\/p>\n<\/div>\n\n

\n

Objective:<\/strong>\u00a0To evaluate the effectiveness and safety of the combination of granulocyte-monocyte apheresis (GMA) after loss of response (LOR) to anti-tumor necrosis factor (TNF) agents in ulcerative colitis (UC).\u00a0Materials and methods:<\/strong>\u00a0A retrospective, multicenter study was performed in 11 inflammatory bowel disease (IBD) Units. Clinical remission was defined as a partial Mayo score \u22642. The effectiveness of the treatment was evaluated by the partial Mayo score and the rate of anti-TNF intensification, switch, swap or colectomy.\u00a0Results:<\/strong>\u00a0Forty-seven patients with ulcerative colitis were included (mean age 35 years, mean disease duration 52 months, 66% male and 59% extensive colitis). Twenty-three subjects were receiving infliximab, eighteen adalimumab and six golimumab. GMA was combined after a primary non-response (49%) or secondary loss of response (51%) to anti-TNF therapy. We observed a significant decrease in partial Mayo score and fecal calprotectin after GMA. Fifteen patients (32%) responded to the combination therapy without anti-TNF intensification, switch, swap or colectomy. Eight patients (17%) underwent colectomy. Two patients (4%) presented adverse events related to the technique.\u00a0Conclusions:<\/strong>\u00a0Combination of GMA and anti-tumor necrosis factor is a safe and effective treatment after the loss of response to these biologic agents, with a significant decrease of the clinical disease activity and biomarkers, in a population with limited therapeutic alternatives.<\/p>\n<\/div>\n\n

\n

https:\/\/pubmed.ncbi.nlm.nih.gov\/30982369\/<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

Iago Rodr\u00edguez-Lago 1, Laura Sempere 2, Ana Guti\u00e9rrez 2 3, Andrea N\u00fa\u00f1ez 4, Eduardo Leo Carnerero 4, Esther Hinojosa 5, Mar\u00eda Mora 5, Fiorella Ca\u00f1ete 6, Miriam Ma\u00f1osa 6, Claudia Herrera 7, Bel\u00e9n Beltr\u00e1n 8, Ana For\u00e9s 9, Dolores Arjona 10, Manuel Barreiro-de Acosta 11, Sam Khorrami 12, Urko Aguirre 13, Daniel Ginard 12, Jos\u00e9 Luis Cabriada 1 , Scand J Gastroenterol 2019 Apr;54(4):459-464. Objective:\u00a0To evaluate the effectiveness and safety of the combination of granulocyte-monocyte apheresis (GMA) after loss of response (LOR) to anti-tumor necrosis factor (TNF) agents in ulcerative colitis (UC).\u00a0Materials […]<\/p>\n","protected":false},"template":"","scientific_tags":[70],"class_list":["post-3924","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-anti-tnf"],"acf":{"sc_authors":"https:\/\/pubmed.ncbi.nlm.nih.gov\/30982369\/<\/a>"},"yoast_head":"\nGranulocyte-monocyte apheresis: an alternative combination therapy after loss of response to anti-TNF agents in ulcerative colitis. - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulocyte-monocyte-apheresis-an-alternative-combination-therapy-after-loss-of-response-to-anti-tnf-agents-in-ulcerative-colitis\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Granulocyte-monocyte apheresis: an alternative combination therapy after loss of response to anti-TNF agents in ulcerative colitis. - Adacyte\" \/>\n<meta property=\"og:description\" content=\"Iago Rodr\u00edguez-Lago 1, Laura Sempere 2, Ana Guti\u00e9rrez 2 3, Andrea N\u00fa\u00f1ez 4, Eduardo Leo Carnerero 4, Esther Hinojosa 5, Mar\u00eda Mora 5, Fiorella Ca\u00f1ete 6, Miriam Ma\u00f1osa 6, Claudia Herrera 7, Bel\u00e9n Beltr\u00e1n 8, Ana For\u00e9s 9, Dolores Arjona 10, Manuel Barreiro-de Acosta 11, Sam Khorrami 12, Urko Aguirre 13, Daniel Ginard 12, Jos\u00e9 Luis Cabriada 1 , Scand J Gastroenterol 2019 Apr;54(4):459-464. Objective:\u00a0To evaluate the effectiveness and safety of the combination of granulocyte-monocyte apheresis (GMA) after loss of response (LOR) to anti-tumor necrosis factor (TNF) agents in ulcerative colitis (UC).\u00a0Materials […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulocyte-monocyte-apheresis-an-alternative-combination-therapy-after-loss-of-response-to-anti-tnf-agents-in-ulcerative-colitis\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2024-05-02T09:11:51+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulocyte-monocyte-apheresis-an-alternative-combination-therapy-after-loss-of-response-to-anti-tnf-agents-in-ulcerative-colitis\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulocyte-monocyte-apheresis-an-alternative-combination-therapy-after-loss-of-response-to-anti-tnf-agents-in-ulcerative-colitis\/\",\"name\":\"Granulocyte-monocyte apheresis: an alternative combination therapy after loss of response to anti-TNF agents in ulcerative colitis. - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2019-04-18T07:07:00+00:00\",\"dateModified\":\"2024-05-02T09:11:51+00:00\",\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulocyte-monocyte-apheresis-an-alternative-combination-therapy-after-loss-of-response-to-anti-tnf-agents-in-ulcerative-colitis\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Granulocyte-monocyte apheresis: an alternative combination therapy after loss of response to anti-TNF agents in ulcerative colitis. - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulocyte-monocyte-apheresis-an-alternative-combination-therapy-after-loss-of-response-to-anti-tnf-agents-in-ulcerative-colitis\/","og_locale":"es_ES","og_type":"article","og_title":"Granulocyte-monocyte apheresis: an alternative combination therapy after loss of response to anti-TNF agents in ulcerative colitis. - Adacyte","og_description":"Iago Rodr\u00edguez-Lago 1, Laura Sempere 2, Ana Guti\u00e9rrez 2 3, Andrea N\u00fa\u00f1ez 4, Eduardo Leo Carnerero 4, Esther Hinojosa 5, Mar\u00eda Mora 5, Fiorella Ca\u00f1ete 6, Miriam Ma\u00f1osa 6, Claudia Herrera 7, Bel\u00e9n Beltr\u00e1n 8, Ana For\u00e9s 9, Dolores Arjona 10, Manuel Barreiro-de Acosta 11, Sam Khorrami 12, Urko Aguirre 13, Daniel Ginard 12, Jos\u00e9 Luis Cabriada 1 , Scand J Gastroenterol 2019 Apr;54(4):459-464. Objective:\u00a0To evaluate the effectiveness and safety of the combination of granulocyte-monocyte apheresis (GMA) after loss of response (LOR) to anti-tumor necrosis factor (TNF) agents in ulcerative colitis (UC).\u00a0Materials […]","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulocyte-monocyte-apheresis-an-alternative-combination-therapy-after-loss-of-response-to-anti-tnf-agents-in-ulcerative-colitis\/","og_site_name":"Adacyte","article_modified_time":"2024-05-02T09:11:51+00:00","twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulocyte-monocyte-apheresis-an-alternative-combination-therapy-after-loss-of-response-to-anti-tnf-agents-in-ulcerative-colitis\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulocyte-monocyte-apheresis-an-alternative-combination-therapy-after-loss-of-response-to-anti-tnf-agents-in-ulcerative-colitis\/","name":"Granulocyte-monocyte apheresis: an alternative combination therapy after loss of response to anti-TNF agents in ulcerative colitis. - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2019-04-18T07:07:00+00:00","dateModified":"2024-05-02T09:11:51+00:00","inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/granulocyte-monocyte-apheresis-an-alternative-combination-therapy-after-loss-of-response-to-anti-tnf-agents-in-ulcerative-colitis\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific-corner\/3924","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/media?parent=3924"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/es\/wp-json\/wp\/v2\/scientific_tags?post=3924"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}